Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma
NCT00849407 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2019-03-07
Summary
Though it is generally accepted that exposure to sunlight is a major causative factor for skin cancer, the risk for developing melanoma is not directly linked to sun exposure such as in non-melanoma skin cancer. Therefore, a dual pathway has been proposed, distinguishing melanoma that develops on skin that is chronically exposed to sunlight from those that occur on skin that is normally protected. The risk for each type of melanoma is believed to be determined in part by genetic factors. To define these markers reproducibly, the investigators plan to establish a large cohort with comprehensive information regarding sun sensitivity (skin type), history of experienced sun exposure, skin pigmentation phenotypes, total number of nevi, and other types of skin tumors in a central European population. The investigators will obtain blood from all participants for DNA as well as serum analyses. Based on the finding that genetic variants of the melanocortin-1 receptor (MC1R) gene, associated with red hair and fair skin, have been shown to be associated with increased risk for melanoma, particularly those harboring BRAF mutations, the investigators will now focus on the study of recently discovered genetic variants associated with pigmentation. Furthermore, the investigators will study the relation of these variants with oncogenic mutations of melanoma in BRAF, RAS and c-Kit. The study of other genetic variants will follow, once a sufficiently large cohort has been established to reveal an independent genetic risk factor in a multivariate analysis including potential covariates as mentioned above. The identification of genetic risk factors for melanoma will not only help identify individuals with increased risk but also improve our understanding of the molecular background of the development of melanoma.
Conditions
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-10-31
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- Austria
Study Locations
More Related Trials
-
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00729950 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database
NCT05426239 ·Status: COMPLETED
-
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
NCT06994208 ·Status: RECRUITING
-
Retrospective Register for Uveal Melanoma
NCT05733728 ·Status: RECRUITING
-
Risk Stratification Among Individuals Who Have Many Moles on Their Skin
NCT03080948 ·Status: COMPLETED
-
Study of Families With Melanoma
NCT00445783 ·Status: UNKNOWN
-
Melanomas Excised in Primary Care vs Secondary Care Excision
NCT03169036 ·Status: COMPLETED
-
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
NCT01482260 ·Status: COMPLETED
-
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
NCT00996827 ·Status: TERMINATED
-
Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its Precursors
NCT05842421 ·Status: COMPLETED ·Phase: NA
-
Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin
NCT01085396 ·Status: TERMINATED
-
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
NCT01376713 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Total Body Skin Examination on Skin Cancer Detection
NCT00765193 ·Status: COMPLETED ·Phase: NA
-
Feasibility and Functionality of fPAM Imaging in Melanoma
NCT00776945 ·Status: TERMINATED
-
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
NCT00672321 ·Status: UNKNOWN
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550 ·Status: RECRUITING
-
Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma
NCT05641012 ·Status: UNKNOWN
-
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
NCT00003789 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
NCT00633516 ·Status: COMPLETED
-
Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690
NCT00937781 ·Status: COMPLETED
-
Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance
NCT03666325 ·Status: UNKNOWN ·Phase: PHASE2
-
MoleGazer Development Feasibility Study
NCT05015816 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
NCT06809491 ·Status: ACTIVE_NOT_RECRUITING
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED